Sunday 18 October 2026
Export RNA’s income statement to Excel — free account
Atrium Therapeutics, Inc.
RNA
Atrium Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.8 million, up 72.1% from fiscal 2024. Revenue growth for three consecutive years.
7.67
0.15
−1.92%
Follow RNA
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | — | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | 0 | 2 | 7 | 9 | 9 | 10 | 11 | 19 | ||||
| Gross margin, % | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |||||
| EBT | — | — | (11) | (25) | (44) | (118) | (174) | (212) | (322) | (685) | |||||
| EBT margin, % | — | — | (2,959.37) | (1,066.58) | (653.53) | (1,265.38) | (1,886.33) | (2,219.87) | (2,957.71) | (3,650.39) | |||||
| Net income | — | — | — | — | — | — | — | — | — | — | |||||
| Depreciation | — | — | — | — | — | — | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | — | — | — | — | |||||
| Cash flow | — | — | — | — | — | — | — | — | — | — | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | |||||
| Book value | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Shares, m | — | — | — | — | — | — | — | — | — | — | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| P/B | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/FCF | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | — | — | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | — | — | — | — | — | — | — | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 85 | 317 | 381 | 571 | 531 | 1,444 | 1,603 | ||||
| Total debt | — | — | — | 2 | — | — | — | — | — | — | |||||
| Net debt | — | — | — | (93) | (328) | (406) | (611) | (595) | (1,501) | (1,697) | |||||
| Shareholders’ equity | — | — | — | 69 | 306 | 381 | 578 | 501 | 1,425 | 1,689 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | 0.00 | (51.05) | (20.59) | (30.99) | (32.63) | (33.49) | (29.40) | (38.88) | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | 0.00 | 0.00 | 99.98 | 94.00 | 64.08 | 45.67 | 44.04 | 55.42 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Atrium Therapeutics, Inc. vs peers (Q) = latest quarter vs a year earlier
Atrium Therapeutics, Inc. (RNA) key facts
- Strength: Atrium Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.8 million, up 72.1% from fiscal 2024.
- As of October 16, 2026, RNA traded at $7.67, a market capitalization of $174.2 million.
- Return on equity was 55.4% and debt-to-equity 0.00.